APL Healthcare Limited Dolutegravir Export Data — India (DGFT 2022–2026)

Name: APL Healthcare Limited Dolutegravir Export Records India — #6 Exporter, 51 Shipments, $2.5M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus
Published: 2026-04-01T00:00:00Z
License: https://transdatanexus.com/terms-and-conditions

Suresh Sormare

Dolutegravir

India Pharmaceutical Trade Intelligence

$4.2B104 Suppliers145 CountriesHS 30049099

ExportsIndia → BOTSWANA75.3%India → TANZANIA6.1%

ImportsCANADA → India$1.0M UNITED STATES → India$970.9K

#1 Buyer: AFRICURE PHARMACEUTICALS

APL Healthcare Limited — Dolutegravir Exporter #6 | $2.5M Trade Value | TransData Nexus | TransData Nexus

APL Healthcare Limited — Dolutegravir Exporter Profile

Indian Pharmaceutical Exporter · #6 for Dolutegravir · $2.5M export value · DGFT Verified

APL Healthcare Limited is the #6 Indian exporter of Dolutegravir with $2.5M in export value and 51 verified shipments. APL Healthcare Limited holds a 0.1% market share in Dolutegravir exports across 9 countries. The company exports 17 pharmaceutical products worth $27.3M across 11 therapeutic categories.

APL Healthcare Limited — Dolutegravir Export Profile: Buyers & Destinations

APL Healthcare Limited Dolutegravir export treemap — buyers and destination countries | TransData Nexus

Where Does APL Healthcare Limited Export Dolutegravir?

Country	Value	Shipments	Share
TANZANIA	$1.1M	23	45.1%
MYANMAR	$550.0K	11	21.6%
NIGERIA	$300.0K	6	11.8%
SOUTH AFRICA	$200.0K	4	7.8%

Who Are the Top Buyers of Dolutegravir from APL Healthcare Limited?

Buyer	Country	Value	Orders
CHEMONICS INTERNATIONAL INC	TANZANIA	$550.0K	11
XXEMOXXCS XXTERXXTIOXXL IXX	TANZANIA	$550.0K	11
XXOPSXXYANXXR	MYANMAR	$400.0K	8
XXEMOXXCS XXTERXXTIOXXL IXX XXEMOXXCS XXTERXXTIO	TOGO	$300.0K	6
UNOPS MYANMAR NO 12 O	MYANMAR	$150.0K	3
XXSOLXXIONXX	NEPAL	$100.0K	2
XXROGXX SOXXH AXXICAXXPTYXXLIMITEDX	SOUTH AFRICA	$100.0K	2
CHEMONICS INTERNATIONAL INC CHEMONICS INTERNATIO	NIGERIA	$100.0K	2
I SOLUTIONS POLANERBAAN 11	MOZAMBIQUE	$100.0K	2
XXSOLXXIONXX POXXNERXXAN XX	NIGERIA	$50.0K	1

APL Healthcare Limited supplies Dolutegravir to 13 buyers globally. The largest buyer is CHEMONICS INTERNATIONAL INC (TANZANIA), followed by XXEMOXXCS XXTERXXTIOXXL IXX (TANZANIA) and XXOPSXXYANXXR (MYANMAR). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.

What Dolutegravir Formulations Does APL Healthcare Limited Export?

Product Description / Formulation	Value	Shipments
DOLUTEGRAVIR LAMIVUDINE AND TENOFOVIR	$2.0M	41
DOLUTEGRAVIR, LAMIVUDINE AND TENOFOVIR	$500.0K	10

APL Healthcare Limited exports 2 distinct Dolutegravir formulations including tablets, capsules, syrups, and combination drugs. The top formulation is DOLUTEGRAVIR LAMIVUDINE AND TENOFOVIR with 41 shipments worth $2.0M. Notable combination products include fixed-dose combinations with other active ingredients, meeting diverse global regulatory requirements.

How Does APL Healthcare Limited Compare to Nearest Dolutegravir Exporters?

Exporters ranked immediately above and below #6 by export value

#	Supplier	Export Value	Shipments	Countries	Avg/Shipment
11	MYLAN LABORATORIES LIMITED	$5.5M	110	20	$50.0K
7	SUN PHARMACEUTICAL INDUSTRIES LIMITED	$3.5M	69	14	$50.0K
6	APL HEALTHCARE LIMITED ★	$2.5M	51	9	$50.0K
5	STRIDES PHARMA SCIENCE LIMITED	$1.9M	39	12	$50.0K
13	BHARAT PARENTERALS LIMITED	$1.4M	28	1	$50.0K

APL Healthcare Limited ranks #6 among 104 Indian Dolutegravir exporters. Average shipment value of $50.0K compared to the market average of $1.4M. The closest competitors by value are MYLAN LABORATORIES LIMITED and SUN PHARMACEUTICAL INDUSTRIES LIMITED.

Which Indian Ports Ship Dolutegravir Exports?

Port	Shipments	% Share
SAHAR AIR	610	18.3%
NHAVA SHEVA SEA (INNSA1)	465	14.0%
JNPT/ NHAVA SHEVA SEA	316	9.5%
SAHAR AIR CARGO ACC (INBOM4)	284	8.5%
JNPT	180	5.4%
HYDERABAD ACC (INHYD4)	164	4.9%
HYDERABAD AIR	147	4.4%
DELHI AIR	137	4.1%

Geopolitical & Trade Policy Impact on APL Healthcare Limited's Dolutegravir Exports

The current geopolitical landscape presents both challenges and opportunities for Indian pharmaceutical exporters like APL Healthcare. The Israel-Iran conflict has disrupted Red Sea shipping routes, leading to increased freight costs and extended transit times. These disruptions are particularly impactful for time-sensitive pharmaceutical shipments, necessitating strategic adjustments in logistics and inventory management. (pharmaceuticalcommerce.com)

Conversely, US-China trade tensions have prompted the United States to seek alternative pharmaceutical suppliers, potentially benefiting Indian exporters. However, the looming threat of US tariffs on pharmaceutical imports adds a layer of uncertainty. In March 2025, Indian pharma exports to the US surged by 74% amid tariff concerns, indicating proactive measures by exporters to mitigate potential impacts. (business-standard.com)

The recent India-European Union Free Trade Agreement, signed in January 2026, is poised to eliminate tariffs on pharmaceuticals, enhancing market access for Indian exporters. This development offers APL Healthcare an opportunity to strengthen its presence in the European market, provided it aligns with EU regulatory standards. (en.wikipedia.org)

APL Healthcare Limited — Regulatory Compliance & Quality Standards

Compliance with international regulatory standards is paramount for Indian pharmaceutical exporters. India has made significant strides in this area, with 752 FDA-approved, 2,050 WHO GMP-certified, and 286 EDQM-approved manufacturing sites as of 2024. (business-standard.com) This robust compliance framework enhances the credibility of Indian pharmaceuticals in global markets.

For APL Healthcare, maintaining and enhancing compliance with FDA, WHO, and EU GMP standards is crucial. Adherence to evolving quality requirements not only ensures market access but also builds trust with international partners. Continuous investment in quality assurance and regulatory affairs will be essential to navigate the complex global pharmaceutical landscape.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Analysis Methodology

1.Product Matching: Dolutegravir shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
2.Supplier Identification: APL Healthcare Limited matched across shipments using name normalization, accounting for company name formatting variations.
3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
4.Verified Records: This page is backed by 51 individual customs records matching APL Healthcare Limited exporting Dolutegravir, covering 2 formulations to 9 countries via 13 buyers.

Government-Sourced Data

Official DGFT customs records

Transparent Methodology

Calculations fully disclosed above

Global Coverage

Exports to 145+ countries, 592+ buyers

Expert-Reviewed

Analyzed by pharmaceutical trade specialists

Dolutegravir

Dolutegravir

APL Healthcare Limited — Dolutegravir Exporter Profile

APL Healthcare Limited — Dolutegravir Export Profile: Buyers & Destinations

Where Does APL Healthcare Limited Export Dolutegravir?

Who Are the Top Buyers of Dolutegravir from APL Healthcare Limited?

What Is India's Total Dolutegravir Export Value and How Much Does APL Healthcare Limited Contribute?

What Is the Average Shipment Value for APL Healthcare Limited's Dolutegravir Exports?

How Does APL Healthcare Limited Compare to Other Indian Dolutegravir Exporters?

What Dolutegravir Formulations Does APL Healthcare Limited Export?

Regulatory Requirements: Exporting Dolutegravir to Key Markets

Nigeria — NAFDAC

How Does APL Healthcare Limited Compare to Nearest Dolutegravir Exporters?

Which Indian Ports Ship Dolutegravir Exports?

What Other Antiviral & HIV Medications Products Does APL Healthcare Limited Export?

Geopolitical & Trade Policy Impact on APL Healthcare Limited's Dolutegravir Exports

APL Healthcare Limited — Regulatory Compliance & Quality Standards

About APL Healthcare Limited

Market Intelligence

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Primary Data Source

Analysis Methodology

Get Dolutegravir Export Data from APL Healthcare Limited

Dolutegravir Stats

Company Overview

Top Products by APL Healthcare Limited

Related Analysis

Need Detailed Export Data?

Data Source